LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE1.7700
- TODAY'S CHANGE (%)-0.1300 (-6.8421%)
- Bid / Lots1.7600/ 50
- Ask / Lots2.0200/ 8
- Open / Previous Close1.8000 / 1.9000
- Day Range
- 52 Week Range
- Volume89,681
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:32 ET | 20351 | 1.8 |
| 09:37 ET | 10661 | 1.825 |
| 10:08 ET | 500 | 1.85 |
| 10:09 ET | 173 | 1.8682 |
| 10:11 ET | 200 | 1.8365 |
| 10:26 ET | 200 | 1.8126 |
| 10:45 ET | 100 | 1.82 |
| 10:47 ET | 1000 | 1.82 |
| 10:58 ET | 1100 | 1.8299 |
| 11:02 ET | 100 | 1.825 |
| 11:12 ET | 100 | 1.83 |
| 11:36 ET | 400 | 1.8391 |
| 11:38 ET | 500 | 1.8301 |
| 11:56 ET | 2000 | 1.835 |
| 12:12 ET | 100 | 1.825 |
| 12:44 ET | 106 | 1.825 |
| 12:50 ET | 300 | 1.81 |
| 01:18 ET | 6944 | 1.85 |
| 01:29 ET | 19289 | 1.77 |
| 01:36 ET | 100 | 1.805 |
| 01:58 ET | 100 | 1.8 |
| 02:12 ET | 100 | 1.805 |
| 02:14 ET | 12627 | 1.76 |
| 02:20 ET | 2632 | 1.78 |
| 02:36 ET | 450 | 1.79 |
| 03:14 ET | 3670 | 1.79 |
| 03:33 ET | 100 | 1.8 |
| 04:00 ET | 632 | 1.77 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 49.9M | -2.0x | --- |
Kronos Bio Inc | 59.7M | -0.5x | --- |
Atara Biotherapeutics Inc | 55.0M | -0.3x | --- |
DURECT Corp | 41.6M | -2.5x | --- |
Affimed NV | 49.6M | -0.6x | --- |
BioLine RX Ltd | 37.5M | -0.6x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.5M |
|---|---|
Revenue (TTM) | $7.4M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.90 |
Book Value | $1.95 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 6.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -371.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
